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Abstract
Background: The kynurenine (KYN) pathway has been shown to be altered in several diseases which compromise
the central nervous system (CNS) including infectious diseases such as bacterial meningitis (BM). The aim of this
study was to assess single nucleotide polymorphisms (SNPs) in four genes of KYN pathway in patients with
meningitis and their correlation with markers of immune response in BM.
Methods: One hundred and one individuals were enrolled in this study to investigate SNPs in the following genes:
indoleamine-2,3-dioxygenase (IDO1 gene), kynureninase (KYNU gene), kynurenine aminotransferase I (CCBL1 gene),
and kynurenine aminotransferase II (AADAT gene). SNP analyses were performed by primer-introduced restriction
analysis-PCR (PIRA-PCR) followed by RFLP. Cytokines were measured using multiplex bead assay while
immunoglobulins (IG) by immunodiffusion plates and NF-kappaB and c-Jun by dot blot assay.
Results: The variant allele of SNP AADAT+401C/T showed prevalent frequency in patients with BM. A significant
decrease (p < 0.05) in TNF-a, IL-1b, IL-6, MIP-1aCCL3 and MIP-1b/CCL4 levels was observed in BM patients
homozygous (TT) to the SNP AADAT+401C/T. Furthermore, a significant (p < 0.05) decrease in cell count was
observed in cerebrospinal fluid (CSF) from patients with TT genotype. In addition, an increase in the IgG level in
adults (p < 0.05) was observed. The variant allele for KYNU+715G/A was found with low frequency in the groups,
and the SNPs in IDO1+434T/G, KYNU+693G/A, CCBL1+164T/C, and AADAT+650C/T had no frequency in this
population.
Conclusions: This study is the first report of an association of SNP AADAT+401C/T with the host immune response
to BM, suggesting that this SNP may affect the host ability in recruitment of leukocytes to the infection site. This
finding may contribute to identifying potential targets for pharmacological intervention as adjuvant therapy for BM.
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Background
Bacterial meningitis (BM) is a severe infectious disease
of the central nervous system (CNS) associated with
acute inflammation that contributes to the development
of subsequent brain damage. Despite the availability of
effective antimicrobial therapy and intensive care, the
outcome of meningitis remains associated with a high
mortality. Moreover, brain and/or cochlear damage
occur in up to 50% of the survivors [1]. An overactive
immune response and the subsequent oxidative stress
production, rather than the bacterial pathogen per se,
are thought to be responsible for the neuronal damage,
such as hearing loss and cognitive impairment [2].
Extensive research has been done in the last decades
on the role of tryptophan (TRP) metabolism in the CNS
under normal and pathological conditions. In recent
years, a clear association has been made between trypto-
phan catabolism and inflammatory reactions in a vast
array of disease states. Much of the focus of this
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research has centered on the kynurenine pathway of
tryptophan degradation and the immune response [3,4].
Bacterial infections and lipopolysaccharide (LPS) appli-
cation are strong inducers of indoleamine-2,3-dioxygen-
ase (IDO), the enzyme responsible for converting
tryptophan to kynurenine (KYN) in the brain [3,4]. The
kynurenine pathway is activated by inflammatory media-
tors, e.g., free radicals and cytokines, which up-regulate
IDO1 gene [5]. In sequence, KYN is converted to 3-
hydroxykynurenine (3-HK) by kynurenine-3-hydroxylase
(KMO). Both KYN and 3-HK can be oxidized by kynur-
eninase (KYNU) to anthranilic acid (AA) or 3-hydro-
xyantrhanilic acid (3-HAA), respectively; or they can be
transaminated by kynurenine aminotransferase (KAT) to
kynurenic acid (KYNA) or xanthurenic acid (XA),
respectively. Finally, 3-HAA can be oxidized to quinoli-
nic acid (QUINA) by 3-hydroxyanthranilic acid oxidase
(3-HAO) [3,4].
The rate of metabolism of TRP into the oxidative
KYN pathway is controlled by IDO enzyme, which is
induced, among other factors, by interleukin-1-beta (IL-
1b), and tumor-necrosis factor alpha (TNF-a) [6,7].
These two pro-inflammatory cytokines are up-regulated
in BM. TNF-a mediates many of the pathophysiological
changes characteristic of BM, including blood-brain-bar-
rier (BBB) breakdown, generation of the neutrophilic
inflammation, increase in cerebral metabolism, oxygen
consumption and cerebral blood flow [8,9]. On the
other side, QUINA induces astrocytes to produce the
pro-inflammatory chemokines monocyte chemoattrac-
tant protein (MCP-1/CCL2) and interleukin-8 (IL-8/
CXCL8). These findings suggest that QUINA may be
critical in the amplification of brain inflammation [10].
In contrast, KYNA was able to attenuate LPS-induced
TNF-a secretion in a dose-dependent manner, acting as
a ligand for the receptor for G protein-coupled receptor
35 (GPR35) [11].
Neurotoxic and neuroprotective activities have been
attributed to different intermediary products of the KYN
pathway. For example, QUINA acts as an agonist at N-
methyl-D-aspartate (NMDA) receptors [12] and may
cause neuronal excitotoxicity [13,14]. On the other
hand, KYNA plays a protective role by acting as an
antagonist of NMDA receptors [15,16]. Further, 3-HK
and 3-HAA generate reactive oxygen species and, thus,
induce neuronal damage [17,18].
Accumulation of neurotoxic intermediates of the KYN
pathway was observed in the cortex and hippocampus
of rats during the early and late phases of acute experi-
mental bacterial meningitis [19]. Data suggesting that
concentrations of KYN pathway metabolites are signifi-
cantly altered in human patients with BM compared
with controls have already been reported [20]. The KYN
pathway is also induced in other diseases associated
with inflammation-induced brain injury, such as Hun-
tington’s disease [21], schizophrenia [22], multiple
sclerosis AIDS-dementia complex and cerebral malaria
[23,24]. Association between the activation of the KYN
pathway and inflammatory mediators has also been
established and a negative feedback mechanism that
downmodulates neuroinflammation in experimental
models was proposed [for review see [4,25]].
In general, bacterial microorganisms that cause BM
are oropharyngeal commensal and the disease develop-
ment occurs from a previous infection, as sinusitis or
otitis, with the blood-brain barrier breaching. Thus, the
incidence of BM could be avoided by an efficient innate
and acquired immune response. Concerning the involve-
ment of KYN pathway with inflammatory response, the
aim of this study was to investigate if single nucleotide
polymorphisms (SNPs) in the KYN pathway genes could
affect the immune response and be associated to BM.
The identification of SNPs may be useful for characteri-
zation of populations susceptible to developing the dis-
ease, the infection severity and, consequently, the
outcome. In the present study, we have attempted to
study SNP in KYN pathway genes in meningitis patients
in order to determine if any significant variation is asso-
ciated with the disease. The analysis was based on pri-
mer introduced restriction analysis-PCR (PIRA-PCR)
followed by RFLP. The analysis also associated the geno-
types with the levels of cytokines, cell account, immuno-
globulins, NF-kappaB, and c-Jun present in the
cerebrospinal fluid (CSF) or plasma of the patients.
Methods
Patients and samples
Blood and CSF samples were obtained from 47 patients
who were admitted at the Hospital Giselda Trigueiro
(reference for Infectious Diseases in Natal-RN, Brazil)
and had a positive diagnosis for BM. These diagnostics
obtained from routine tests performed in the hospital
were based on detection of the pathogen in the CSF by
gram staining, bacterial culture, or antigen testing, and
the presence of CSF pleocytosis. In total, 101 individuals
(56 men and 45 women) were included in this study,
with 28 individuals less than 18 years old, 69 adults
between 19 and 60 years old, and 4 individuals aged
over 60. Of the 47 patients with positive diagnosis for
BM, 15 were diagnosed with S. pneumonia, 6 with N.
meningitides, 7 with other pathogens, and 19 without
specified etiology. The clinical parameters observed were
cell count (2.887,6 ± 4.120,6 cells/mm3), glucose (35.9 ±
33.30 g/ml) and protein (178.1 ± 156.0 mg/d). Indivi-
duals in therapies or with others diseases (as AIDS) that
affect the immune and inflammatory responses (e.g. the
cytokines expression) were not included in the analysis,
since these conditions might interfere in the results.
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Aliquots of blood and CSF collected for the diagnosis
of the disease were used in this work. Samples of CSF
were collected just upon lumbar puncture and centri-
fuged at 720 g for 5 min. Supernatants were frozen and
stored at -80°C before any further procedure. Blood
samples were processed by centrifugation at 2,880 g for
3 min to separate plasma from pellet. Both were frozen
and stored at -80°C. As control group, 54 blood samples
were obtained from health volunteers and from patients
attended at the Hospital Giselda Trigueiro who had the
negative diagnosis for infectious disease. These patients
were used as control since no infection was confirmed
and all parameters were normal. CSF and blood were
collected for diagnosis routine and all data about clinical
parameters as glucose, pleocytosis, cytokines level were
obtained from these patients. In health volunteers, CSF
sample was not collected, since lumbar puncture is a
very invasive method. This project was approved by the
Brazilian Ethics Committee (CONEP, CAAE -
0052.1.051.000.05) and written consent was obtained
from all patients involved. For children included in this
study, the informed consent was obtained from their
parents or guardians.
Oligonucleotides
A survey of genes for KYN pathway enzymes was car-
ried out using the NCBI database http://www.ncbi.nlm.
nih.gov. The localization of protein conserved domains
was obtained through the alignment of this region with
the mRNA sequence using the program GeneWise,
Expasy http://www.ebi.ac.uk/Wise2/index.html and the
exons of interest were chosen by analysis of alignments
of mRNA with the genomic DNA obtained with the
tool Spidey from the NCBI database. SNPs were
searched in functional domain regions of KYN pathway
enzymes in the Human Genome Sequence (Table 1).
Primers were designed for PIRA-PCR (Table 1) using
Primer2 software [26].
PIRA-PCR and Genotyping
The genomic DNA samples were extracted from blood
samples (2-5 ml) using a salting out procedure [27].
PCR amplification was carried out in a total volume of
25 μl containing 2.5 μl of 10×PCR buffer, 200 ng of
genomic DNA, 0.1 mM of dATP, dGTP, dCTP and
dTTP (Invitrogen), 20 pmol of each primer, 1.5 mol/l
MgCl2, and 1 U Taq polymerase (Invitrogen). Amplifi-
cations were performed in a DNA thermal cycler
(Eppendorf) for 35 cycles. The reaction conditions were:
pre-denaturation at 94°C for 5 min, followed by 35 cycles
of denaturation at 94°C for 45 s, annealing shown in
Table 1 for 45 s, and extension at 72°C for 1 min. The
sequences of primers and the lengths of the PCR pro-
ducts analyzed are also shown in Table 1. The primers
contain a single-base mismatch leading to the produc-
tion of PCR products containing a restriction site. Prior
to digestion, samples were electrophoresed on 2% agar-
ose gels containing ethidium bromide to verify amplifi-
cation. An aliquot of each PCR product was digested
with the respective enzyme (Table 1) in the buffer sup-
plied by the manufacturer. The product of digestion was
visualized in polyacrylamide gels 8% stained with silver
[28]. The analysis of genotyping was blinded and all
samples were replicated.
Measurement of chemokines and cytokines
Chemokine and cytokine levels in CSF were measured by
a Bio-Plex 200 suspension array system (Bio-Rad) using
microsphere-based multiplex assays. A human cytokine
Lincoplex Kit (HCYTO-60k, Lincoplex®, Linco Research
Inc.) was used in this assay. This kit allows the detection
of TNF-a, IL-6, IL-1b, INF-g, IL-10, IL-1Ra, MIP-1a/
CCL3 and MIP-1b/CCL4, MCP-1/CCL2, G-CSF, IL-8/
CXCL8, and GM-CSF. The assay was performed as pre-
viously described by Gehre et al., 2008 [29]. Cytokine
concentrations were calculated using a standard curve
derived from a recombinant standard cytokine by Bio-
Table 1 SNP data: primer sequences, annealing temperatures, PCR product sizes, and enzyme restrictions
SNP RS_ID Alleles Primer Sequence (5’® 3’) Annealing
Temp. (°C)
Product
size (pb)
Restriction enzyme
IDO1+434T/G rs4463407 T/G F: TCAGGTCTTGCCAAGAACTA
R: CAGTTTGCCAAGACACAGTC
53.5 101 MaeI
KYNU+693G/A rs2304705 G/A F: CGGACTTAACATTGAAGAAAGTATGC
R: TTTGAGGAAAATGAAGAAAAAAATCA
55.0 115 HpyCH4V
KYNU+715G/A rs6743085 G/A F: ATATCCTCTATTCTTAAGGTTTCATC
R: ATTTAGATCGGCAATATGAAAT
51.5 101 FokI
CCBL1+164T/C rs17853193 T/C F:CCAAGGCGTGACTTCAGGGC
R:GGCACATGGGGAGAGTGTAGGACTAA
58.0 119 HaeIII
AADAT+650G/T rs17852900 G/T F:ATAGATCCATTTGTCCTTGACTGGAT
R:ACATTTTTTGCTTTAGAATTCCAGAG
58.0 113 FokI
AADAT+401C/T rs1480544 C/T F:ACTATAGAAATCAATAACCCTAGAA
R:GAAAACAAATTCTTATAGCCTG
50.0 111 MboII
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Plex Manager software. Samples were assessed undiluted
and serially diluted to allow quantification of cytokines
over a broad range (3.2-10,000 pg/ml).
Measurements of immunoglobulins
The total levels of IgG and IgA were measured from the
patients’ plasma, using quantitative radial immunodiffu-
sion plates (Diffu-plate, Biocientífica SA), according to
the manufacturer’s instructions. Due to the low quantity
of biological material, it was not possible to make the
determination in all the patients.
Dot Blot assay to NF-kappaB and c-Jun
Dot blot assay was performed using an adapted protocol
based on Towbin et al. (1979) [30]. Briefly, proteins
were obtained from aliquots containing 10 μl of CSF
that were previously centrifuged for 15,000 g, 4°C, for 5
min. Samples were transferred to an activated PVDF
membrane (Qbiogene) and nonspecific binding was
avoided by incubation in a blocking buffer (5% skimmed
milk (non-fat) diluted in TBST) for one hour. Mem-
branes were then probed with primary monoclonal anti-
bodies against NF-kappaB (Santa Cruz Biotechnology)
and c-Jun (R&D systems) diluted in blocking buffer.
After washing, blots were incubated with secondary
antibodies conjugated to horseradish-peroxidase (Santa
Cruz Biotechnology) diluted in blocking solution. Pro-
tein-antibody reactions were detected through reaction
with 0.5% DAB (Across Organics), AcNH4 (50 mM, pH
5.0), and 0.06% H2O2 (Merck). Detection of b-actin anti-
body was used as control of endogenous protein expres-
sion. For the quantification of protein levels, dots were
photographed and images were analyzed with the ImageJ
program (NIH, public domain). Estimation of the rela-
tive NF-kappaB and c-Jun levels was obtained by the
ratio in relation to the b-actin level.
Statistical analysis
Allelic frequencies were determined by direct count of
the alleles. Genotypic distributions were examined for
significant departure from Hardy-Weinberg equilibrium
by classical method of X2-test (two-tailed) using Helix
SVS program. The significance among differences in alle-
lic and genotypic frequencies observed between all ana-
lyzed groups was evaluated by X2-test (two-tailed) using
WINPEPI program. Differences in levels of inflammatory
markers were analyzed by non-parametric t-test Mann-
Whitney U (two-tailed) and spearman correlation test
was carried out with GraphPad-Prism5 software. The
findings were considered significant when P < 0.05.
Results
The results obtained for the SNP AADAT+401C/T
showed that among the 101 analyzed individuals the
allelic frequencies were 0.59 and 0.40 for the alleles C
and T respectively. Moreover, the analysis of the sub-
groups shows differences in the allelic and genotypic
frequencies. All groups are in Hardy-Weinberg equili-
brium. In the BM patients, the frequency of T allele was
0.51, while for the control patients the frequency was
0.3 (P = 0.004, OR = 2.49). An increase for the TT gen-
otype was also observed in the BM group, suggesting
the association of this SNP with the disease (Table 2).
In this population (101 individuals), the variant allele
frequency observed for the SNP KYNU+715G/A was
0.0104. No significant differences were observed
between BM patients and control group (Table 2).
The variant alleles for SNPs KYNU+693G/A, CCBL1
+164T/C, AADAT+650G/T and IDO1+434T/G were not
found in this population. The frequency of these SNPs
should be very low and it was not possible to find the
polymorphic allele among the 101 analyzed samples.
Thus, this analysis does not suggest association of SNPs
KYNU+715G/A, KYNU+693G/A, CCBL1+164T/C,
AADAT+650G/T, and IDO1+434T/G with BM. How-
ever, the SNP AADAT+401C/T may be associated with
the disease, since allelic and genotypic frequencies show
statistical significance between BM patients and control
group.
Concentrations of cytokines and chemokines were
measured in CSF samples of BM patients. A significant
(p < 0.05) decrease in levels of TNF-a, IL-1b, IL-6,
MIP-1a/CCL3 and MIP-1b/CCL4 was observed in
patients homozygous (TT) to the SNP AADAT+401C/
T (Figure 1a). No significant differences were observed
for INF-g, IL-10, IL-1Ra, MCP-1/CCL2, G-CSF, IL-8/
CXCL8 and GM-CSF levels (data not shown) and in
NF-kappaB and c-Jun expression (data not shown). A
significant reduction in cell count was observed in
patients with TT genotype (Figure 1b). The correlation
analyses (Table 3) showed that the cell count has sig-
nificant correlation with TNF-a, IL-1b, IL-6, MIP-
1aCCL3 and MIP-1b/CCL4 in all patients. However,
the analyses in relation to genotype showed differences
between CC or TT genotypes. Significant correlation
between cell count and TNF-a, IL-6, MIP-1aCCL3
and MIP-1b/CCL4 was observed in patients with TT
genotype, while for patients with CC genotype signifi-
cant correlation was only observed between cell count
and IL-6.
Due to differences in acquired immune response in
children (<18 years old) and adults (≥ 18 years old),
each group was subjected to a distinct analysis of IgG
level. Significant increase in the IgG level was observed
in adult patients with TT genotype (Figure 1c). The
number of children in our sample was not enough for
the statistical analysis of IgG level, however the same
tendency was observed (data not shown).
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Discussion
In the present study, the association of SNPs in key
enzymes of the KYN pathway with bacterial meningitis
was investigated in Brazilian patients. The TT genotype
for SNP AADAT+401C/T show a high frequency in
patients with BM compared with the control group
(Table 2). This result shows indicative that the variant
allele AADAT+401C/T may play a relevant role in
inflammatory regulation during the development of the
disease. However, the number of patients included in
this work is limited and further studies are required in
larger cohorts.
The enzyme KATII (product of AADAT gene) is
responsible for the formation of KYNA found in glial
and neuronal cells [31]. The SNP AADAT+401C/T is
located in a putative exonic splicing silencers (ESSs),
and mutations in these regions may result in quantita-
tive changes in the production canonical mRNAs and
peptide production that are likely to contribute signifi-
cantly to inter-individual phenotypic variability [32].
Bacterial microorganisms that cause BM are usually
oropharyngeal commensal in a fraction of the popula-
tion. The disease develops when the pathogens gain
access to the CSF space either via the blood stream in
bacteremia or from an adjacent infection e.g from sinu-
sitis. Thus, the incidence of BM could be lowered by an
efficient immune defense [33]. A critical role of cyto-
kines and chemokines has been carefully established in
models of bacterial meningitis. Following the injection
of LPS from gram-negative meningeal pathogens as
Neisseria meningitides or cell-wall components from
pneumococci, the rapid increase of proinflammatory
cytokines (as TNF-a, IL-1b and IL-6) can be documen-
ted in CSF, which is followed by the recruitment of
granulocytes and increased CSF protein concentrations
[34-36].
Table 2 Genotypic and allelic frequencies of SNPs AADAT+401C/T and KYNU+715G/A
Genotype AADAT+401C/T BM Cases 47 (%) Controls 54 (%) OR (95% CI)a P-valueb CC vs TTd
CC 11 (23) 28 (52) 0.275 (0.150 to 0.507) <0.0001c P = 0.021 c
CT 24 (51) 19 (35) 1.933 (1.095 to 3.411) 0.0223c OR = 0.23 (0.07 to 0.72)
TT 12 (25) 7 (13) 2.231 (1.066 to 4.667) 0.0305c
Frequency of T allele 0.51 0.30 2.429 (1.359 to 4.339) 0.0038c
Genotype KYNU+715G/A BM Cases 46 (%) Controls 52 (%) OR (95% CI)a P-valueb GG vs AAd
GG 41 (89) 43 (82) 1.776 (0.7916 to 3.985) 0.1598 P = 0.38
GA 2 (4) 4 (7) 0.5536 (0.1568 to 1.954) 0.3521 OR = 1.91(0.45 to 8.00)
AA 3 (7) 6 (11) 0.6090 (0.2260 to 1.641) 0.3230
Frequency of A allele 0.08 0.15 0.4928 (0.1988 to 1.221) 0.1208
a ORs and probability values at 95% CI for disease status are shown.
b Values were calculated with the X2-test (two-tailed) comparing controls and case patients.
c Significant P value (P < 0.05).
d Analysis of distribution of the contrasting genotypes. Values calculated with X2-test (two-tailed)
Figure 1 Markers of immune response associated to SNP
AADAT+401C/T. a) Cytokine and chemokine concentration in CSF
samples of BM patients in relation to the genotype for SNP AADAT
+401C/T; b) Cell counts associated to AADAT+401C/T genotype; c)
IgG and IgA concentration in plasma samples from adults patients
in relation to the genotype for SNP AADAT+401C/T. All P values are
related to TT compared to CC genotype.
Table 3 Correlation between cell count and cytokines
and chemokines level in BM patients
All patients TNF-a IL-6 IL-1b MIP-1b MIP-1a
Spearman r 0.6181 0.5308 0.6218 0.5295 0.4287
P value <0.0001a 0.0002 a <0.0001a 0.0002a 0.003a
CC genotype TNF-a IL-6 IL-1b MIP-1b MIP-1a
Spearman r 0.2848 0.8283 0.2439 0.3404 0.2364
P value 0.4250 0.0031a 0.4971 0.3358 0.5109
TT genotype TNF-a IL-6 IL-1b MIP-1b MIP-1a
Spearman r 0.8500 0.8034 0.6390 0.9500 0.7833
P value 0.0061 a 0.0138 a 0.666 0.0004 a 0.0172 a
- Correlation analysis done using Spearman test two-tailed (cell count vs
cytokine or chemokine level).
a Significant P value (P < 0.05).
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High levels of TNF-a, IL-6 and IL-1b are characteris-
tic of meningitis processes and may be associated with
disease severity and the occurrence of sequelae [37].
Numerous studies have demonstrated that these cyto-
kines are important to activation of chemokines (such
as MIP-1a/CCL3 and MIP-1b/CCL4) involved with the
leukocyte recruitment to the infection site for effective
pathogen eradication [38]. In several models of infec-
tion, the deficiency in these cytokines and chemokines
was associated with the decrease in the clearance of
pathogens, development of invasive disease, and high
mortality [39-41]. Furthermore, the correlation of che-
mokines with cell count in CSF during BM have also
been reported [38,42]. Low levels of IL-1b, TNF-a and
IL-6 in nasopharyngeal secretion were observed in chil-
dren with recurrent episodes of acute otitis media [43],
an important cause of meningitis.
Our results suggest that the SNP AADAT+401C/T
may affect the expression of markers of the immune
response characteristic in meningitis. We observed a sig-
nificant reduction (P < 0.05) in the level of TNF-a, IL-
1b, IL-6, MIP-1a/CCL3 and MIP-1b/CCL4 in BM
patients who had the TT genotype (Figure 1a) and also
a reduction in cell count (Figure 1b) with the highest
correlation with the cytokines and chemokines (Table
3), suggesting a reduced ability in leukocyte recruitment
in these patients.
The KYN pathway has been described as involved in
the regulation of inflammatory response. However the
mechanisms of regulation are not well understood
[3,4,25]. NF-kappaB and Ap-1 (Fos/Jun) play a crucial
role during induction of inflammatory response to BM.
These transcriptional factors are involved in very com-
plex cascades of events that lead to induction of cyto-
kines, chemokines and adhesion molecules [37,44].
Differences in expression of NF-kappaB and c-Jun in
relation to genotypes were not observed in our work.
These data suggest that the effect of the SNP AADAT
+401C/T may be downstream of the activation of NF-
kappaB during inflammatory response. Recently, Ogasa-
wara et al. (2009) [45] showed that the activation of NF-
kappaB through the PI3K pathways is required for the
IDO expression induced by hemoglobin in bone mar-
row-derived myeloid dendritic cells. This finding sug-
gests that activation of NF-kappaB precedes the KYN
pathway activation.
KYNA was identified as a ligand for the receptor for
GPR35, proposing a novel mechanism by which KYNA
may regulate peripheral cellular responses through acti-
vation of GPR35. KYNA was able to attenuate LPS-
induced TNF-a secretion in a dose-dependent manner.
The predominant expression of GPR35 in immune cells
and the elevation of KYNA levels during inflammation
suggested that this receptor-ligand complex may play
important roles in immunological regulation. Because
the tryptophan metabolic pathway is activated by pro-
inflammatory stimuli, the anti-inflammatory effect of
KYNA provides an interesting feedback mechanism in
modulating immune responses [11].
Positive correlation between CSF KYNA levels with
age and IgG and b2-microglobulin levels was observed
in human subjects without neurological disease [46].
These authors propose that the enhancement of CSF
IgG and b2-microglobulin levels would suggest an acti-
vation of the immune system during aging. Moreover,
the increased KYNA metabolism would be involved in
the hypofunction of the glutamatergic and/or nicotinic
cholinergic neurotransmission in the CNS aging. How-
ever, the relationship between KYNA changes and acti-
vation of IgG and b2-microglobulin levels with aging is
not yet clear. In our work, we also observed an associa-
tion of TT genotype (SNP AADAT+401C/T) with an
increase of IgG level. This evidence indicates that the
KYNA level affects the antibody production by an
unknown mechanism.
Although the population studied in this work has small
size, our sampling represents the epidemiological and
clinical spectrum of BM in our region. The low frequency
of meningitis cases and the poor public health system in
Natal (Brazil) did not allow the more accurate stratifica-
tion of the patients and the examination of the influence
of level-altered chemokines and cytokines in severity or
sequelae in patients, pointing the need to extend the ana-
lysis done in this work for a large numbers of patients.
Conclusions
Our data suggest that among the allele variants studied
in this work the SNP AADAT+401C/T may be asso-
ciated with meningitis. The allele variants for KYNU
+715G/A, KYNU+693G/A, CCBL1+164T/C, AADAT
+650G/T, and IDO1+434T/G had a lower frequency and
probably are not associated with meningitis. In this
research, we obtained indicatives that the presence of
SNP in the AADAT+401C/T affects the expression of
markers of the immune response to meningitis. How-
ever, these evidences need to be confirmed in further
studies with larger cohorts. A better understanding of
this correlation and the mechanisms involved is essential
to identify potential targets for pharmacological inter-
vention as an adjuvant therapy in BM as well as the pos-
sibility of stratification for risk assessment, genetic
predisposition, diagnosis, and prognosis.
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